1. PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

2. PCSK9 Development Thus Far

3. PCSK9 Monoclonal Antibodies

4. PCSK9 Inhibition in Patients With Hypercholesterolemia Receiving Statin Therapy

6. ODYSSEY LONG-TERM Safety Results

7. PCSK9 CV Outcomes Trials

8. PCSK9 Monoclonal Antibodies in Patients With HeFH

13. Reductions in Atherogenic Lipid Parameters With the PCSK9 Inhibitor Monotherapy

14. Background

17. Effect of PCSK9 Inhibition on Lp(a)

18. Lp(a) Background

21. Forward Looking Perspective: Potential Clinical Impact of PCSK9 Monoclonal Antibodies

22. PCSK9 Monoclonal Antibodies Which Patients Are Good Candidates?

23. On Statin Levels and Risk for CV Events

24. ODYSSEY LONG TERM TEAEs Reported in > 5% of Patients

25. PCSK9 Monoclonal Antibodies Additional Risk Factors to Assess Patient Risk

26. Abbreviations

27. Abbreviations (cont)